POLICYBZR Q2 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,167 Cr
verified against source
Revenue YoY
44%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
PB Fintech delivered 44% YoY revenue growth to INR 1,167 crore in Q2 FY25, with PAT improving by INR 72 crore to INR 51 crore despite elevated operating expenses. The health and life insurance business continues to exceed expectations at 69% YoY new premium growth, with total insurance premium reaching INR 5,450 crore (ARR of ~INR 22,000 crore). Credit-linked revenue was INR 143 crore, while new initiatives grew 87% and turned contribution-positive. Adjusted EBITDA margin improved from minus 26% to minus 12% YoY. Management acknowledged over-investing in H1 (~$4-5 million extra operating expenses) but expects correction in H2. The medium-term guidance of ~30% growth remains intact despite current outperformance. Paisabazaar faces prolonged unsecured credit slowdown requiring cost corrective actions. PB Health initiative remains in discussion phase with board approval pending; management views it as an enabler for 5% incremental industry growth rather than a standalone financial investment.
Colored figures show movement against the previous available record.
Guidance to track
- Despite current 60-70% growth rates, management maintains 30% as the steady-state medium-term target for core insurance fresh business growth, consistent with long-term guidance provided since IPO.
- Management expects FY25 free cash flow of approximately $60 million, with FY26 projected to exceed $100 million as profitability continues to improve.
- Policybazaar board may consider a one-time investment of up to $100 million in the PB Health initiative post-approval, positioned as strategic enablement rather than financial investment.
- ESOP amortization expenses are expected to stabilize and potentially decrease going forward from current levels.
Risks flagged
- Unsecured credit business has underperformed expectations for 4-5 quarters versus anticipated 2-quarter dip. Regulatory headwinds, elevated delinquencies, and reduced prime/below-prime acquisition are industry-wide issues. Management is taking operating cost corrective actions.
- The healthcare hospital network initiative is at least a 10-year project with no entity finalized yet. Benefits of 1-2% premium growth impact expected in first 5 years, with material benefits only visible beyond that horizon. Board approval not yet obtained.
- Q1-Q2 saw ~$1 million/month extra operational costs due to capacity build-ahead of growth. While growth has validated the investment, any growth slowdown could result in underutilized capacity and margin pressure.
- Life insurers are reportedly renegotiating terms on guaranteed return products with distributors. While management states this is a small portion of PB Fintech's business and primarily affects other channels, any industry-wide changes could impact product mix and margins.
Key quotes
- Don't get used to the 60%-70% kind of growth. It's good. It's been happening. So far, it does not seem like it's changing. But listen, this is unreal growth. Our long-term guidance, our midterm guidance continues to be 30%-ish.
- Policybazaar is not investing in this venture from a financial return perspective. Policybazaar, if it is investing, is investing from an enablement perspective because this venture benefits Policybazaar a lot, a huge amount, right? And the industry a huge amount.
- Our three-year CAGR is about 41% on fresh business... what we are saying is maybe the next three, four years, CAGR is going to be maybe 30%.
- PB Partners is not a massively profitable business ever. So somebody who believes that POSP will start generating the same kind of margins like contribution margins like Policybazaar has is dreaming because that's impossible.
Research modules